Murepavadin
Also known as: POL7080, RG7929, Inhaled murepavadin
Investigational macrocyclic peptide antibiotic for Pseudomonas aeruginosa. IV Phase 3 trials were halted in 2019 over kidney injury. Not approved.
Last updated
Mechanism of Action
Murepavadin is a synthetic beta-hairpin peptidomimetic modeled on the host-defense peptide protegrin I. It binds LptD, an outer-membrane protein that transports lipopolysaccharide to the cell surface in Pseudomonas aeruginosa, blocking outer-membrane assembly. This target is specific to Pseudomonas, so it has a very narrow spectrum and little activity against other bacteria.
- Half-life
- Not well established in patients; a few hours IV in healthy volunteers
- Administration Routes
- Intravenous, Inhaled
- Research Status
- Clinical
Reported Benefits
- Studied for hospital-acquired and ventilator-associated pneumonia caused by Pseudomonas aeruginosa (IV, halted)
- Inhaled formulation studied for chronic Pseudomonas lung infection in cystic fibrosis and bronchiectasis
- Potent in-vitro activity against multidrug-resistant Pseudomonas isolates
Potential Side Effects
- Acute kidney injury (rates higher than expected in IV Phase 3 trials)
- Infusion-related symptoms in early trials
- Long-term safety not established
Common Dosing
No approved dose. Phase 1 studies tested single and multiple IV ascending doses and, later, inhaled doses in healthy volunteers; the IV Phase 3 regimens were stopped. Use outside a clinical trial is not appropriate.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Investigational: not established
- Kidney impairment was the key safety concern in IV trials
No documented stacking partners for Murepavadin yet.
- View
Pharmacokinetics and Safety of Intravenous Murepavadin Infusion in Healthy Adult Subjects Administered Single and Multiple Ascending Doses
2018
- View
Pharmacokinetics, Tolerability, and Safety of Murepavadin, a Novel Antipseudomonal Antibiotic, in Subjects with Mild, Moderate, or Severe Renal Function Impairment
2018
- View
Murepavadin: a new antibiotic class in the pipeline
2018